<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Parvovirus B19 (PVB19) induced severe aplastic <z:hpo ids='HP_0001903'>anaemia</z:hpo> (SAA) or <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) is rare, and haematopoietic stem cell transplantation (HSCT) in this condition has not been reported so far </plain></SENT>
<SENT sid="1" pm="."><plain>6 children with SAA (n=4) or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (n=2) caused by <z:hpo ids='HP_0011009'>acute</z:hpo> PVB19 <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> underwent HSCT under the protection of intravenous immunoglobulines </plain></SENT>
<SENT sid="2" pm="."><plain>The 4 children with SAA received matched HLA bone marrow from a sibling (n=3) or peripheral unrelated blood stem cells (n=1) </plain></SENT>
<SENT sid="3" pm="."><plain>1 patient had delayed erythrocyte engraftment, whereas 3 patients had an uneventful transplantation course </plain></SENT>
<SENT sid="4" pm="."><plain>HSCT in one of the 2 children with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> was complicated by poor graft function, the other patient engrafted without complications </plain></SENT>
<SENT sid="5" pm="."><plain>In conclusion, HSCT in children with PVB19 induced SAA or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> is feasible, even though some patients may develop delayed engraftment or prolonged poor graft function </plain></SENT>
</text></document>